vs
Pacira BioSciences, Inc.（PCRX）与Tecnoglass Inc.（TGLS）财务数据对比。点击上方公司名可切换其他公司
Tecnoglass Inc.的季度营收约是Pacira BioSciences, Inc.的1.4倍（$245.3M vs $177.4M），Tecnoglass Inc.净利率更高（10.6% vs 1.6%，领先9.0%），Pacira BioSciences, Inc.同比增速更快（5.0% vs 2.4%），过去两年Tecnoglass Inc.的营收复合增速更高（12.8% vs -0.2%）
Pacira BioSciences是一家专科制药企业，专注于非阿片类疼痛管理药物的研发与商业化，核心产品线面向术后镇痛场景，服务以美国为主的医院、门诊手术中心等医疗服务机构，同时推进部分国际市场的拓展工作。
Tecnoglass Inc.是一家领先的建筑玻璃、铝制门窗及相关建材生产商，主要服务北美及拉美地区的住宅和商业建筑领域，为新建及翻新项目提供定制化、高能效的建筑解决方案。
PCRX vs TGLS — 直观对比
营收规模更大
TGLS
是对方的1.4倍
$177.4M
营收增速更快
PCRX
高出2.6%
2.4%
净利率更高
TGLS
高出9.0%
1.6%
两年增速更快
TGLS
近两年复合增速
-0.2%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $177.4M | $245.3M |
| 净利润 | $2.9M | $26.1M |
| 毛利率 | — | 40.0% |
| 营业利润率 | 3.9% | 18.3% |
| 净利率 | 1.6% | 10.6% |
| 营收同比 | 5.0% | 2.4% |
| 净利润同比 | — | -44.5% |
| 每股收益（稀释后） | $0.07 | $0.57 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PCRXTGLS
| Q1 26 | $177.4M | — | ||
| Q4 25 | $196.9M | $245.3M | ||
| Q3 25 | $179.5M | $260.5M | ||
| Q2 25 | $181.1M | $255.5M | ||
| Q1 25 | $168.9M | $222.3M | ||
| Q4 24 | $187.3M | $239.6M | ||
| Q3 24 | $168.6M | $238.3M | ||
| Q2 24 | $178.0M | $219.7M |
净利润PCRXTGLS
| Q1 26 | $2.9M | — | ||
| Q4 25 | — | $26.1M | ||
| Q3 25 | $5.4M | $47.2M | ||
| Q2 25 | $-4.8M | $44.1M | ||
| Q1 25 | $4.8M | $42.2M | ||
| Q4 24 | — | $47.0M | ||
| Q3 24 | $-143.5M | $49.5M | ||
| Q2 24 | $18.9M | $35.0M |
毛利率PCRXTGLS
| Q1 26 | — | — | ||
| Q4 25 | 79.5% | 40.0% | ||
| Q3 25 | 80.9% | 42.7% | ||
| Q2 25 | 77.4% | 44.7% | ||
| Q1 25 | 79.7% | 43.9% | ||
| Q4 24 | 78.7% | 44.5% | ||
| Q3 24 | 76.9% | 45.8% | ||
| Q2 24 | 75.1% | 40.8% |
营业利润率PCRXTGLS
| Q1 26 | 3.9% | — | ||
| Q4 25 | 1.2% | 18.3% | ||
| Q3 25 | 3.5% | 25.1% | ||
| Q2 25 | 4.7% | 24.0% | ||
| Q1 25 | 1.2% | 26.7% | ||
| Q4 24 | 13.2% | 28.0% | ||
| Q3 24 | -82.8% | 28.4% | ||
| Q2 24 | 15.9% | 23.3% |
净利率PCRXTGLS
| Q1 26 | 1.6% | — | ||
| Q4 25 | — | 10.6% | ||
| Q3 25 | 3.0% | 18.1% | ||
| Q2 25 | -2.7% | 17.3% | ||
| Q1 25 | 2.8% | 19.0% | ||
| Q4 24 | — | 19.6% | ||
| Q3 24 | -85.1% | 20.8% | ||
| Q2 24 | 10.6% | 15.9% |
每股收益（稀释后）PCRXTGLS
| Q1 26 | $0.07 | — | ||
| Q4 25 | $0.05 | $0.57 | ||
| Q3 25 | $0.12 | $1.01 | ||
| Q2 25 | $-0.11 | $0.94 | ||
| Q1 25 | $0.10 | $0.90 | ||
| Q4 24 | $0.38 | $1.00 | ||
| Q3 24 | $-3.11 | $1.05 | ||
| Q2 24 | $0.39 | $0.75 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $144.3M | $104.1M |
| 总债务越低越好 | — | $174.4M |
| 股东权益账面价值 | $653.9M | $713.1M |
| 总资产 | $1.2B | $1.3B |
| 负债/权益比越低杠杆越低 | — | 0.24× |
8季度趋势，按日历期对齐
现金及短期投资PCRXTGLS
| Q1 26 | $144.3M | — | ||
| Q4 25 | $238.4M | $104.1M | ||
| Q3 25 | $246.3M | $127.1M | ||
| Q2 25 | $445.9M | $140.9M | ||
| Q1 25 | $493.6M | $160.2M | ||
| Q4 24 | $484.6M | $137.5M | ||
| Q3 24 | $453.8M | $124.8M | ||
| Q2 24 | $404.2M | $129.5M |
总债务PCRXTGLS
| Q1 26 | — | — | ||
| Q4 25 | $372.2M | $174.4M | ||
| Q3 25 | $376.7M | $114.7M | ||
| Q2 25 | $580.5M | $110.6M | ||
| Q1 25 | $583.4M | $110.6M | ||
| Q4 24 | $585.3M | $111.1M | ||
| Q3 24 | — | $126.8M | ||
| Q2 24 | — | $144.7M |
股东权益PCRXTGLS
| Q1 26 | $653.9M | — | ||
| Q4 25 | $693.1M | $713.1M | ||
| Q3 25 | $727.2M | $764.0M | ||
| Q2 25 | $757.8M | $736.0M | ||
| Q1 25 | $798.5M | $685.1M | ||
| Q4 24 | $778.3M | $631.2M | ||
| Q3 24 | $749.6M | $613.3M | ||
| Q2 24 | $879.3M | $574.8M |
总资产PCRXTGLS
| Q1 26 | $1.2B | — | ||
| Q4 25 | $1.3B | $1.3B | ||
| Q3 25 | $1.3B | $1.2B | ||
| Q2 25 | $1.5B | $1.2B | ||
| Q1 25 | $1.6B | $1.1B | ||
| Q4 24 | $1.6B | $1.0B | ||
| Q3 24 | $1.5B | $996.3M | ||
| Q2 24 | $1.6B | $942.5M |
负债/权益比PCRXTGLS
| Q1 26 | — | — | ||
| Q4 25 | 0.54× | 0.24× | ||
| Q3 25 | 0.52× | 0.15× | ||
| Q2 25 | 0.77× | 0.15× | ||
| Q1 25 | 0.73× | 0.16× | ||
| Q4 24 | 0.75× | 0.18× | ||
| Q3 24 | — | 0.21× | ||
| Q2 24 | — | 0.25× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $31.0M |
| 自由现金流经营现金流 - 资本支出 | — | $11.4M |
| 自由现金流率自由现金流/营收 | — | 4.7% |
| 资本支出强度资本支出/营收 | — | 8.0% |
| 现金转化率经营现金流/净利润 | — | 1.19× |
| 过去12个月自由现金流最近4个季度 | — | $34.5M |
8季度趋势，按日历期对齐
经营现金流PCRXTGLS
| Q1 26 | — | — | ||
| Q4 25 | $43.7M | $31.0M | ||
| Q3 25 | $60.8M | $40.0M | ||
| Q2 25 | $12.0M | $17.9M | ||
| Q1 25 | $35.5M | $46.9M | ||
| Q4 24 | $33.1M | $61.1M | ||
| Q3 24 | $53.9M | $41.5M | ||
| Q2 24 | $53.2M | $34.5M |
自由现金流PCRXTGLS
| Q1 26 | — | — | ||
| Q4 25 | $43.5M | $11.4M | ||
| Q3 25 | $57.0M | $21.2M | ||
| Q2 25 | $9.3M | $-14.7M | ||
| Q1 25 | $26.9M | $16.5M | ||
| Q4 24 | $31.0M | $35.4M | ||
| Q3 24 | $49.8M | $17.8M | ||
| Q2 24 | $51.6M | $14.2M |
自由现金流率PCRXTGLS
| Q1 26 | — | — | ||
| Q4 25 | 22.1% | 4.7% | ||
| Q3 25 | 31.7% | 8.2% | ||
| Q2 25 | 5.1% | -5.7% | ||
| Q1 25 | 15.9% | 7.4% | ||
| Q4 24 | 16.6% | 14.8% | ||
| Q3 24 | 29.6% | 7.5% | ||
| Q2 24 | 29.0% | 6.5% |
资本支出强度PCRXTGLS
| Q1 26 | — | — | ||
| Q4 25 | 0.1% | 8.0% | ||
| Q3 25 | 2.2% | 7.2% | ||
| Q2 25 | 1.5% | 12.7% | ||
| Q1 25 | 5.1% | 13.7% | ||
| Q4 24 | 1.1% | 10.7% | ||
| Q3 24 | 2.4% | 9.9% | ||
| Q2 24 | 0.9% | 9.2% |
现金转化率PCRXTGLS
| Q1 26 | — | — | ||
| Q4 25 | — | 1.19× | ||
| Q3 25 | 11.20× | 0.85× | ||
| Q2 25 | — | 0.41× | ||
| Q1 25 | 7.37× | 1.11× | ||
| Q4 24 | — | 1.30× | ||
| Q3 24 | — | 0.84× | ||
| Q2 24 | 2.82× | 0.98× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
TGLS
| Product Sales | $164.2M | 67% |
| Fixed Price Contracts | $81.1M | 33% |
| Related Party | $692.0K | 0% |
